introduction
Osteonecrosis of the jaws has been recently recognized as a potential complication of BF treatment [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , mainly by i.v. regimen, for malignancy-associated hypercalcemia and prevention of bone fractures in patients with metastatic bone disease or multiple myeloma [13] [14] [15] . With regard to the social impact and limitedly to the underestimated cumulative incidence, as taken from retrospective studies among patients receiving i.v. BF, it has been calculated a range from 0.8% to 12% [8, 16] . Pathogenetic mechanisms of this condition are not completely understood and management of affected patients is mostly on the basis of the clinical guidelines drawn from expert opinions and case series analysis [17, 18] . Among aminobisphosphonates, pamidronate and zoledronate have shown the most consistent effects for the treatment of bone metastases in cancer, with zoledronate being more potent in vitro than pamidronate [19] . Amino-bisphosphonates inhibit osteoclasts at different stages, binding selectively to hydroxyapatite and accumulating in sites of active bone remodeling. Once BF are stored in bone, their release is dependent on the rate of bone remodeling [20] . In addition, amino-bisphosphonates have antiangiogenic properties both in vitro and in vivo. Clinically, these lesions appear as nonhealing-exposed bone areas, which can be accompanied by fistulization, purulent discharge and pain. The current nomenclature for bisphosphonate-related osteonecrosis of jawbone (BRONJ) lesions reflects the prevailing hypothesis that such a condition is a form of osteonecrosis. The need for a higher level of scientific evidence has been already underlined [3] . In fact, the pathogenesis of jawbone disease in patients receiving BF is largely unknown and the biological mechanisms by which BF are responsible for bone remodeling and angiogenesis impairment in human jaws are still uncertain.
Risk factors for BRONJ occurrence are usually grouped in three great categories: (i) drug-related risk factors, (ii) local risk factors, and (iii) demographic/systemic risk factors as extensively reported [16] [17] [18] [19] [20] [21] ; furthermore, other factors have been recently thought to be linked, such as corticosteroids, thalidomide, diabetes, smoking, alcohol use, poor oral hygiene and chemotherapeutic agents [22] [23] [24] [25] [26] [27] (Table 1) .
Because of the proven benefits of i.v. BF, their high BF halflife [28] [29] [30] and the considerable number of prescriptions, some major issues have to be taken into account extendedly both by oncologists and by dentists: (1) therapeutic dental protocol for patients with diagnosis of BRONJ, (2) dental strategies for patients in former or current i.v. BF treatment and in absence of BRONJ signs, and (3) strategies for patients before i.v. BF treatment. On the basis of the literature as providing sometimes unclear indications and our clinical experience, major end points of this paper are providing our protocols for the issues above described and, finally, focusing on a crucial, but not extensively investigated point: the early and correct diagnosis of BRONJ versus metastatic jaw lesions in cancer patients.
As follows, some schemes are provided about the issues 1, 2 and 3, respectively. To examine patients with full or partial dentures for areas of mucosal trauma, especially along the lingual flange region (i.e. mylohyoid ridge) and where palatal and lingual tori and bone exostoses can be present.
To make stable teeth with grade 1 or 2 of dental mobility To make conservative restorative and prosthesis treatments To make acrylic stents or individual trays to cover areas of exposed bone, to protect adjacent soft tissue, to improve comfort and to maintain therapeutic agents in situ In case of necessary tooth extraction (see Table 2 )
Achievement and/or maintenance of a good oral hygiene
Over-gingival scaling Instruction to oral self-hygiene Prescription of antiseptic rinses, such as chlorhexidine 0.12% without alcohol (three times/day) Local application of fluorine Motivation of patients regarding the importance of good dental hygiene
Patient education and reassurance about BRONJ
Delivery of informative papers (e.g. letter to dentistry, information for the patients) Instruction to avoid every elective dental or surgical procedures involving osseous injury during the treatment with BF and at least 5 years after the cessation of bisphosphonate therapy Education to periodic clinical and radiographic follow-up, with frequency depending on seriousness of BRONJ
Pharmacological therapy
Broad-spectrum antibiotic therapy before antibiotic assay according to the regimens described in Table 2 Antifungals, if required, should be prescribed If patient refers pain, systemic analgesics should be prescribed in order to mitigate symptoms 8. Surgery therapy in case of exposed/necrotic bone Debridement and/or sequestrectomy less traumatic as possible, also by means of piezosurgery [31] [32] [33] [34] [35] [36] [37] [38] To avoid the use of vasoconstrictor associated with local anesthetics Resection of the affected bony tissue, less traumatic as possible, also by means of piezosurgery [31] [32] [33] [34] [35] [36] [37] [38] Partial, marginal or segmental resection, eventually followed by a reconstructive therapeutic phase 9. Alternative therapy in case of exposed/necrotic bone Low-level laser therapy using He-Ne or diode laser. Education to clinical and X-ray follow-up, with frequency depending on the number of concomitant risk factors and general dental health Issue 3: dental management of patients before treatment with BF
1. Thorough examination of hard and soft intraoral tissues 2. X-ray of jaws to evaluate the general oral status 3. Achievement of optimal periodontal and dental health Extraction of teeth with partial inclusion (only mucosal inclusion, not bone inclusion) and of teeth with a poor prognosis (e.g. teeth with serious periodontal disease, nonrestorable teeth or unsalvageable with prosthesis) Extraction, in the children, of deciduous teeth with a certain grade of mobility Etiological periodontal therapy and stabilization of teeth with grade 1 or 2 of dental mobility Endodontic treatment of teeth with chronic periodontal lesions Conservative restorative and prosthesis treatments, when necessary Patients with full or partial dentures should be examined for areas of mucosal trauma, especially along the lingual flange region Elimination of local risk factors (e.g. sharp edges of dental crowns, inadequate dental prosthesis, inadequate conservative restorative treatments)
Achievement of a good oral hygiene
Scaling and root planning Instruction to oral self-hygiene Prescription of antiseptic rinses, such as chlorhexidine 0.12% Local application of fluorine Motivation of patients regarding the importance of good dental hygiene
Valuation of risks/benefits to delay the BF therapy
Initiation of bisphosphonate therapy should be delayed until periodontal and dental health is optimized. In order to get clinical and radiographic healing, all invasive dental procedures should be completed at least 3-4 weeks before starting BF therapy Collaboration among treating physician, oncologist, dentist and other specialists involved in the care of the patient.
Patient education and reassurance about BRONJ
Delivery of informative papers (e.g. letter to dentistry, information for the patients) Instructions to avoid every elective dental or surgical procedures involving osseous injury during the treatment with BF and at least 5 years after the cessation of bisphosphonate therapy Instructions to report every early symptom or clinical sign (e.g. pain, swelling) Education to periodic clinical and radiographic follow-up, with frequency depending on the number of concomitant risk factors and general dental health.
Issue 4: diagnosis of BRONJ vs metastatic jaw lesions in cancer patients
It appears that one of the issues requiring to be further addressed are challenges in suspecting and diagnosing metastatic jaw lesions in cancer patients affected by BRONJ due to overlapping clinical and/or radiological appearance. In fact, considering the nature of tumors that generally affect patients requiring bisphosphonates administration and developing jaw osteonecrosis, the occurrence of jawbone metastases is an expectable event. Thus, in a correct diagnostic process it should be always kept in mind, suspected and excluded. This is Table 3 . Protocol in case of not postponed tooth extractions in patients receiving IV BF Discontinuation of BF from 1 to 3 months before and after dento-alveolar surgery, till a complete healing of tissue 1 Broad-spectrum antibiotic therapy 5 days before and 20 days after tooth extraction, until a complete healing of treated tissues occurs, in combination with topical applications of chlorexidine gluconate LLLT both during intra-surgical phase and 1 week after surgical treatment. Five topical applications for 1 minute should be performed. At least three periodic meetings are necessary. The LLLT improve tissue regeneration and decrease the bacterial colonization in the site of surgical procedure.
particularly true at the time of BRONJ onset, when this clinical condition can be correctly diagnosed ruling out metastatic infiltration from the underlying malignancy. However, clinical picture cannot provide any useful parameter; imaging techniques lack specificity and radiologic appearance of BRONJ can be quite variable ranging from osteolytic to osteosclerotic changes, so its differentiation from a metastasis may be very difficult. The only way to accurately identify and exclude metastatic lesions remains histopathological evaluation; it requires biopsy execution, but if we consider when and where carry out to a biopsy many issues remain unsolved. Surgical procedures may lead to worsening or progression of the disease, so, according to current clinical guidelines it is advised a conservative approach and it is recommended that biopsies of the exposed bone should be carried out only whenever metastatic bone disease is suspected. However, we have neither clinical nor radiological signs suggestive of cancer infiltration, thus a strict application of current guidelines might restrict biopsy execution limiting the possibility to rule out jaw metastasis; consequently, the relevance to the patient prognosis of such a differential diagnosis underlines the current contradiction and the need for revising clinical guidelines regarding both biopsy schedule and site selection. Under the latter point of view, the exposed portion of the diseased jawbone could appear as the most convenient site since current guidelines recommend reduction of traumas to soft tissues. However, it is mainly constituted by necrotic tissue, so for the results to be reliable it might be better shifting toward margins of exposed bone. Unfortunately, by now, we have no answer and clinical behavior remains case sensitive on the basis of personal judgment.
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